Comparative Pharmacology
Head-to-head clinical analysis: FONDAPARINUX SODIUM versus HEPARIN SODIUM 20 000 UNITS IN DEXTROSE 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FONDAPARINUX SODIUM versus HEPARIN SODIUM 20 000 UNITS IN DEXTROSE 5.
FONDAPARINUX SODIUM vs HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fondaparinux is a synthetic pentasaccharide that selectively binds to antithrombin III, potentiating its inhibition of factor Xa. This prevents thrombin generation and clot formation.
Heparin sodium binds to antithrombin III, causing a conformational change that accelerates the inactivation of thrombin and factor Xa, and to a lesser extent factors IXa, XIa, and XIIa, thereby inhibiting coagulation. It also inhibits platelet aggregation and prolongs clotting times.
2.5 mg subcutaneously once daily for prophylaxis; 5 mg (body weight <50 kg), 7.5 mg (50-100 kg), or 10 mg (>100 kg) subcutaneously once daily for treatment of venous thromboembolism
Adults: Initial IV bolus 80 units/kg, then continuous IV infusion at 18 units/kg/hour. For therapeutic anticoagulation, adjust to target aPTT 1.5-2.5 times control. Dosing per institutional nomogram.
None Documented
None Documented
Terminal elimination half-life: 17-21 hours (young adults), 21-24 hours (elderly). Provides once-daily dosing for thromboprophylaxis.
Terminal half-life 1.5 hours (range 1-3 hours) for therapeutic doses; dose-dependent, with higher doses prolonging half-life; half-life prolonged in hepatic or renal impairment.
Renal: 80-87% unchanged in urine; biliary/fecal: minimal (<10%)
Renal: 50-60% as unchanged drug via glomerular filtration; hepatic metabolism (desulfation) accounts for minor clearance; fecal elimination negligible (<1%).
Category C
Category A/B
Anticoagulant
Anticoagulant